MCL Literature Feed

This meta-analysis across B-NHLs confirms lenalidomide-based regimens improve OS and PFS, supporting its established role in relapsed/refractory and maintenance settings for MCL.

This preclinical study identifies that SOX11 upregulates the antioxidant PRDX2, promoting chemoresistance in aggressive MCL, and suggests PRDX2 as a novel therapeutic target to overcome drug resistance.

This case report describes a rare presentation of primary, localized orbital mantle cell lymphoma successfully managed with local excision and radiotherapy, highlighting an unusual clinical scenario for this systemic disease.

A transplant-sparing frontline regimen of lenalidomide-R-CHOP/R-HiDAC showed favorable outcomes in TP53 wild-type high-risk MCL, but not TP53-mutated MCL, reinforcing the prognostic power of sequential MRD monitoring.

MYC overexpression is a critical biomarker defining high-risk mantle cell lymphoma, helping to stratify patients with poor prognosis and potentially guiding novel therapeutic approaches for this aggressive disease.

The CAR-T therapy lisocabtagene maraleucel demonstrates high, durable complete responses and a favorable safety profile in heavily pretreated, relapsed/refractory MCL, including high-risk patients.

This retrospective analysis shows peripheral blood Ig-HTS MRD testing (clonoSEQ) effectively predicts relapse earlier than imaging in MCL patients, supporting its use as a surveillance tool post-frontline therapy.

This case report highlights unprovoked venous thromboembolism as a presenting symptom of mantle cell lymphoma, underscoring the need for a prompt malignancy workup in such clinical scenarios.

This article summarizes Israeli national guidelines for administering CAR-T therapy in relapsed/refractory MCL, detailing patient management, toxicity monitoring for CRS and ICANS, and long-term follow-up principles.

The CRM1 inhibitor KPT-330 induces protective autophagy in MCL cells; co-treatment with an autophagy inhibitor like chloroquine results in synergistic cell killing, suggesting a novel combination strategy.

This narrative review of Malaysian B-cell lymphoma research identifies only three mantle cell lymphoma papers, highlighting a significant data gap and the need for more regional epidemiological studies.

This case report describes the rare Warburg effect (severe hypoglycemia, lactic acidosis) in an MCL patient, highlighting its potential for cardiac toxicity and the utility of hemodialysis for stabilization.

Using computational screening and machine learning, this study identifies novel PIM2 inhibitors, presenting a potential new therapeutic target for future drug development in hematologic malignancies, including MCL.

MCL with concurrent EZH2 expression and TP53 mutation is frequent and identifies a patient subgroup with a dismal outcome, establishing a powerful negative prognostic biomarker combination.

This review, while focused on CLL, details the metabolic and toxicity profiles of covalent and non-covalent BTKis, informing MCL management strategies for adverse events and emerging resistance.

This review summarizes fundamental MCL characteristics, including the t(11;14) translocation and key high-risk features (high Ki67, blastoid variant, TP53 mutation) essential for patient risk stratification.

This paper does not study MCL but finds high Notch1 protein expression in methotrexate-associated DLBCL, suggesting a pathogenic role for this pathway, which is also altered in MCL.

Severe neurotoxicity after brexucabtagene autoleucel is common, associated with MRI/EEG changes and longer hospitalization, but importantly does not negatively impact treatment response or survival in MCL patients.

Palbociclib plus venetoclax shows preclinical synergy in ibrutinib-refractory MCL by downregulating MCL1, offering a chemo-free option for patients without RB1 deletion.

Phospho-flow cytometry reveals that high constitutive AKT and inducible STAT5/SYK B-cell receptor signaling activity predicts shorter survival and ibrutinib resistance, offering a functional biomarker for high-risk MCL.

Real-world UK data show first-line ibrutinib is effective and tolerable for older MCL patients, but high-risk subgroups (TP53-mutated, blastoid) have significantly inferior survival, highlighting an unmet need.

This review details BTK inhibitor resistance mechanisms, particularly C481S mutations, and highlights non-covalent BTKi (pirtobrutinib) and PROTACs as key strategies to overcome relapse in MCL.

This large SEER database study identifies being unmarried, particularly widowed, as an independent negative prognostic factor for survival in MCL, underscoring the need for enhanced psychosocial support.

Mendelian randomization analysis reveals that genetically longer telomeres are a causal risk factor for developing hematological malignancies, including MCL, suggesting a potential inherited predisposition for the disease.

Large B-cell lymphoma with IRF4 rearrangement can mimic blastoid MCL by presenting in older adults and expressing CD5, but negativity for Cyclin D1 and SOX11 is crucial for differential diagnosis.

This large retrospective study of orbital lymphomas identifies mantle cell lymphoma as a rare subtype but provides no specific clinical or prognostic data for this particular presentation.

Long-term follow-up confirms rituximab maintenance post-transplant significantly improves overall survival in young, fit MCL patients, establishing this as a standard of care in the frontline setting.

This preclinical study of a bortezomib nanoparticle delivery system in glioblastoma cell lines is not relevant to mantle cell lymphoma.

Palliative radiotherapy provided profound tumor reduction for an elderly patient with blastoid MCL presenting as a rare oropharyngeal mass, demonstrating a personalized, less-intensive frontline treatment option.

This UK real-world study confirms bendamustine-rituximab toxicity rates are similar to clinical trials, identifying MCL histology and poor performance status as key risk factors for serious infections.